-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Disc Medicine, Raises Price Target to $100

Benzinga·09/02/2026 12:37:28
Listen to the news
Wedbush analyst David Nierengarten maintains Disc Medicine (NASDAQ:IRON) with a Outperform and raises the price target from $88 to $100.